理解和处理Covid-19疫苗接种的陷阱(“任何傻瓜都能知道。关键是要理解”)

Q4 Medicine
D. Richter
{"title":"理解和处理Covid-19疫苗接种的陷阱(“任何傻瓜都能知道。关键是要理解”)","authors":"D. Richter","doi":"10.5457/p2005-114.326","DOIUrl":null,"url":null,"abstract":"The aim of this article is to critically review the managing of vaccination over the course of the present COVID-19 pandemic against the knowledge that had already been at hand and the scientific data that had yet to be learned. In the period before vaccines for COVID-19 became available, the startling similarity in epidemiologic behavior between COVID-19 and the Spanish flu could be observed. The development of vaccines against COVID-19 has evolved at an unprecedented speed resulting in highly immunogenic vaccines with incredible protective characteristics covering a relatively short follow-up time in clinical trials. The rollout in the general population turned out to take significantly longer time than the duration of immunity conferred by a 2-dose vaccination schedule (about 3-4 months). Therefore, the SARS-CoV-2 was left with the opportunity for random mutations with each replication cycle, resulting in immune evasion, shortened incubation, shortened serial interval, and increased transmissibility. The short incubation period of COVID-19 requires a steady protective antibody titer to be maintained to avert infection, achieve herd immunity, and terminate the pandemic spread. The protective neutralization titer needed to avert symptomatic infection and infection altogether is about 3% and 20%, respectively, of the mean convalescent titer. The latter corresponds to an absolute titer of 1:10–1:30. The intensity and duration of protective vaccinal and hybrid humoral immunity are explored. From the present perspective, it was naive to believe that a 2-dose vaccination would suffice to counter COVID-19 primarily due to its short incubation and a roll-out that was not catching up with the waning protective vaccinal antibody levels. Besides, the spacing of doses and boosters with respect to previous infection or vaccination, and differences in natural immunity and vaccine-induced immunity (adenovirus-vectored and mRNA) are discussed. The issue of vaccination and multisystem inflammatory syndrome in children is briefly presented. Finally, ethical points are discussed as some vaccine production platforms and neutralization tests use human cell lines derived from aborted fetuses.Conclusion – If the COVID-19 vaccines had been licensed as 3-dose vaccines, with more generous spacing, e.g. 0-2-6 months, providing for quantitatively larger and temporally more durable humoral immunity, that would have enabled attaining a steadier herd immunity and probably a paradoxical earlier effect on stopping the transmission.","PeriodicalId":36516,"journal":{"name":"Central European Journal of Paediatrics","volume":"24 1","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2022-11-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Pitfalls in Understanding and Handling of Covid-19 Vaccination (“Any Fool Can Know. The Point Is to Understand”)\",\"authors\":\"D. Richter\",\"doi\":\"10.5457/p2005-114.326\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"The aim of this article is to critically review the managing of vaccination over the course of the present COVID-19 pandemic against the knowledge that had already been at hand and the scientific data that had yet to be learned. In the period before vaccines for COVID-19 became available, the startling similarity in epidemiologic behavior between COVID-19 and the Spanish flu could be observed. The development of vaccines against COVID-19 has evolved at an unprecedented speed resulting in highly immunogenic vaccines with incredible protective characteristics covering a relatively short follow-up time in clinical trials. The rollout in the general population turned out to take significantly longer time than the duration of immunity conferred by a 2-dose vaccination schedule (about 3-4 months). Therefore, the SARS-CoV-2 was left with the opportunity for random mutations with each replication cycle, resulting in immune evasion, shortened incubation, shortened serial interval, and increased transmissibility. The short incubation period of COVID-19 requires a steady protective antibody titer to be maintained to avert infection, achieve herd immunity, and terminate the pandemic spread. The protective neutralization titer needed to avert symptomatic infection and infection altogether is about 3% and 20%, respectively, of the mean convalescent titer. The latter corresponds to an absolute titer of 1:10–1:30. The intensity and duration of protective vaccinal and hybrid humoral immunity are explored. From the present perspective, it was naive to believe that a 2-dose vaccination would suffice to counter COVID-19 primarily due to its short incubation and a roll-out that was not catching up with the waning protective vaccinal antibody levels. Besides, the spacing of doses and boosters with respect to previous infection or vaccination, and differences in natural immunity and vaccine-induced immunity (adenovirus-vectored and mRNA) are discussed. The issue of vaccination and multisystem inflammatory syndrome in children is briefly presented. Finally, ethical points are discussed as some vaccine production platforms and neutralization tests use human cell lines derived from aborted fetuses.Conclusion – If the COVID-19 vaccines had been licensed as 3-dose vaccines, with more generous spacing, e.g. 0-2-6 months, providing for quantitatively larger and temporally more durable humoral immunity, that would have enabled attaining a steadier herd immunity and probably a paradoxical earlier effect on stopping the transmission.\",\"PeriodicalId\":36516,\"journal\":{\"name\":\"Central European Journal of Paediatrics\",\"volume\":\"24 1\",\"pages\":\"\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2022-11-04\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Central European Journal of Paediatrics\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.5457/p2005-114.326\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q4\",\"JCRName\":\"Medicine\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Central European Journal of Paediatrics","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.5457/p2005-114.326","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"Medicine","Score":null,"Total":0}
引用次数: 0

摘要

本文的目的是根据已有的知识和尚未掌握的科学数据,对当前COVID-19大流行期间的疫苗接种管理进行批判性审查。在COVID-19疫苗问世之前的一段时间里,可以观察到COVID-19和西班牙流感之间惊人的流行病学行为相似性。COVID-19疫苗的开发以前所未有的速度发展,导致高免疫原性疫苗具有令人难以置信的保护特性,在临床试验中随访时间相对较短。事实证明,在普通人群中推广疫苗所需的时间明显长于两剂疫苗接种计划(约3-4个月)所提供的免疫持续时间。因此,SARS-CoV-2在每个复制周期中都有随机突变的机会,从而导致免疫逃避,缩短潜伏期,缩短序列间隔,增加传播性。COVID-19潜伏期短,需要保持稳定的保护性抗体滴度,以避免感染,实现群体免疫,并终止大流行传播。避免症状性感染和感染所需的保护性中和效价分别约为康复期平均效价的3%和20%。后者对应的绝对滴度为1:10-1:30。探讨了保护性疫苗免疫和混合型体液免疫的强度和持续时间。从目前的角度来看,认为接种两剂疫苗就足以对抗COVID-19是天真的,主要原因是它的潜伏期很短,而且疫苗的推出没有赶上保护性疫苗抗体水平的下降。此外,还讨论了与先前感染或疫苗接种有关的剂量和增强剂的间隔,以及自然免疫和疫苗诱导免疫(腺病毒载体和mRNA)的差异。简要介绍了儿童疫苗接种和多系统炎症综合征的问题。最后,讨论了伦理问题,因为一些疫苗生产平台和中和试验使用来自流产胎儿的人类细胞系。结论:如果COVID-19疫苗被批准为3剂疫苗,间隔时间更大,例如0-2-6个月,提供数量上更大、时间上更持久的体液免疫,这将能够实现更稳定的群体免疫,并可能在阻止传播方面产生矛盾的更早效果。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
Pitfalls in Understanding and Handling of Covid-19 Vaccination (“Any Fool Can Know. The Point Is to Understand”)
The aim of this article is to critically review the managing of vaccination over the course of the present COVID-19 pandemic against the knowledge that had already been at hand and the scientific data that had yet to be learned. In the period before vaccines for COVID-19 became available, the startling similarity in epidemiologic behavior between COVID-19 and the Spanish flu could be observed. The development of vaccines against COVID-19 has evolved at an unprecedented speed resulting in highly immunogenic vaccines with incredible protective characteristics covering a relatively short follow-up time in clinical trials. The rollout in the general population turned out to take significantly longer time than the duration of immunity conferred by a 2-dose vaccination schedule (about 3-4 months). Therefore, the SARS-CoV-2 was left with the opportunity for random mutations with each replication cycle, resulting in immune evasion, shortened incubation, shortened serial interval, and increased transmissibility. The short incubation period of COVID-19 requires a steady protective antibody titer to be maintained to avert infection, achieve herd immunity, and terminate the pandemic spread. The protective neutralization titer needed to avert symptomatic infection and infection altogether is about 3% and 20%, respectively, of the mean convalescent titer. The latter corresponds to an absolute titer of 1:10–1:30. The intensity and duration of protective vaccinal and hybrid humoral immunity are explored. From the present perspective, it was naive to believe that a 2-dose vaccination would suffice to counter COVID-19 primarily due to its short incubation and a roll-out that was not catching up with the waning protective vaccinal antibody levels. Besides, the spacing of doses and boosters with respect to previous infection or vaccination, and differences in natural immunity and vaccine-induced immunity (adenovirus-vectored and mRNA) are discussed. The issue of vaccination and multisystem inflammatory syndrome in children is briefly presented. Finally, ethical points are discussed as some vaccine production platforms and neutralization tests use human cell lines derived from aborted fetuses.Conclusion – If the COVID-19 vaccines had been licensed as 3-dose vaccines, with more generous spacing, e.g. 0-2-6 months, providing for quantitatively larger and temporally more durable humoral immunity, that would have enabled attaining a steadier herd immunity and probably a paradoxical earlier effect on stopping the transmission.
求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
Central European Journal of Paediatrics
Central European Journal of Paediatrics Medicine-Pediatrics, Perinatology and Child Health
CiteScore
0.50
自引率
0.00%
发文量
23
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信